Lambrolizumab induced central nervous system (CNS) toxicity.
作者信息
Mandel Jacob J, Olar Adriana, Aldape Kenneth D, Tremont-Lukats Ivo W
机构信息
The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, 1515 Holcombe Blvd Unit 431, Houston, TX 77030-4009, United States; The University of Texas MD Anderson Cancer Center, Department of Pathology, 1515 Holcombe Blvd, Houston, TX 77030-4009, United States.
The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, 1515 Holcombe Blvd Unit 431, Houston, TX 77030-4009, United States; The University of Texas MD Anderson Cancer Center, Department of Pathology, 1515 Holcombe Blvd, Houston, TX 77030-4009, United States.
出版信息
J Neurol Sci. 2014 Sep 15;344(1-2):229-31. doi: 10.1016/j.jns.2014.06.023. Epub 2014 Jun 20.
Abstract
摘要
相似文献
1
Lambrolizumab induced central nervous system (CNS) toxicity.帕博利珠单抗诱发中枢神经系统（CNS）毒性。
J Neurol Sci. 2014 Sep 15;344(1-2):229-31. doi: 10.1016/j.jns.2014.06.023. Epub 2014 Jun 20.
2
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.纳武单抗和派姆单抗作为靶向程序性死亡受体1（PD-1）受体的免疫调节单克隆抗体用于治疗黑色素瘤。
Expert Rev Anticancer Ther. 2015;15(9):981-93. doi: 10.1586/14737140.2015.1074862. Epub 2015 Jul 30.
3
New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.转移性黑色素瘤患者接受 CTLA4 单克隆抗体治疗后新发纵隔和中枢神经系统结节病。
Oncol Res Treat. 2014;37(6):351-3. doi: 10.1159/000362614. Epub 2014 May 12.
4
Pembrolizumab for melanoma- safety profile and future trends.帕博利珠单抗治疗黑色素瘤——安全性概况及未来趋势。
Expert Opin Drug Saf. 2016 Jun;15(6):727-9. doi: 10.1080/14740338.2016.1175430. Epub 2016 Apr 27.
5
[CNS toxicity of antineoplastic drugs].[抗肿瘤药物的中枢神经系统毒性]
Harefuah. 1991 Nov 15;121(10):397-401.
6
Could knee inflammatory synovitis be induced by pembrolizumab?帕博利珠单抗会诱发膝关节炎性滑膜炎吗？
J Oncol Pharm Pract. 2018 Jul;24(5):389-392. doi: 10.1177/1078155217701292. Epub 2017 Mar 29.
7
Risk of cumulative toxicity after complete melanoma response with pembrolizumab.帕博利珠单抗治疗黑色素瘤完全缓解后的累积毒性风险。
BMJ Case Rep. 2017 Feb 1;2017:bcr2016218308. doi: 10.1136/bcr-2016-218308.
8
[Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer].[癌症治疗中免疫调节抗体诱导的自身免疫性内分泌病]
Med Clin (Barc). 2015 Sep 21;145(6):264-8. doi: 10.1016/j.medcli.2015.02.010. Epub 2015 Apr 4.
9
[Molecular target therapy-associated CNS complications].[分子靶向治疗相关的中枢神经系统并发症]
Gan To Kagaku Ryoho. 2008 Oct;35(10):1659-64.
10
A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma.一例在用派姆单抗治疗黑色素瘤的患者中出现的新发抗体阳性重症肌无力病例。
Muscle Nerve. 2017 Jun;55(6):E25-E26. doi: 10.1002/mus.25496. Epub 2017 Mar 23.
引用本文的文献
1
PD-1-induced encephalopathy: a report of 2 cases on neurological toxicities with immune checkpoint inhibitors.程序性死亡受体 1（PD-1）诱导的脑病：2例免疫检查点抑制剂所致神经毒性报告
Transl Cancer Res. 2024 Feb 29;13(2):1196-1207. doi: 10.21037/tcr-23-2043. Epub 2024 Feb 2.
2
Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report.托泊替康致脑疾病相关口吃：1 例胰腺导管腺癌病例报告。
BMC Neurol. 2023 Mar 4;23(1):96. doi: 10.1186/s12883-023-03140-7.
3
Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review).使用 PD-1/PD-L1 抗体治疗癌症患者：不良反应与管理策略（综述）。
Int J Oncol. 2022 Jun;60(6). doi: 10.3892/ijo.2022.5364. Epub 2022 Apr 29.
4
Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention.肿瘤免疫治疗的神经毒性：临床关注的浮现
J Oncol. 2022 Jan 18;2022:4259205. doi: 10.1155/2022/4259205. eCollection 2022.
5
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.免疫检查点抑制剂诱发的无菌性脑膜炎和脑炎：病例系列及叙述性综述
Ther Adv Drug Saf. 2021 Mar 29;12:20420986211004745. doi: 10.1177/20420986211004745. eCollection 2021.
6
Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department.急诊科中免疫检查点疗法免疫相关不良反应的诊断与管理
J Am Coll Emerg Physicians Open. 2020 Aug 30;1(6):1637-1659. doi: 10.1002/emp2.12209. eCollection 2020 Dec.
7
Immune Checkpoint Inhibitors and Neurotoxicity.免疫检查点抑制剂和神经毒性。
Curr Neuropharmacol. 2021;19(8):1246-1263. doi: 10.2174/1570159X19666201230151224.
8
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.与免疫检查点抑制相关的神经免疫相关不良事件。
Curr Oncol Rep. 2019 Nov 27;21(12):108. doi: 10.1007/s11912-019-0859-2.
9
Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.免疫检查点抑制剂所致高级别神经并发症的拟诊与治疗模式
Neurooncol Pract. 2019 Sep;6(5):340-345. doi: 10.1093/nop/npy039. Epub 2018 Oct 4.
10
Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review.纳武单抗相关的急性脱髓鞘性脑炎：一例报告及文献综述
Clin Med Res. 2019 Jun;17(1-2):29-33. doi: 10.3121/cmr.2019.1417.
本文引用的文献
1
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.帕博利珠单抗（MK-3475；抗 PD-1 单克隆抗体）治疗晚期实体瘤患者的 I 期研究。
Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.
2
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.伊匹单抗治疗转移性黑色素瘤患者的非典型神经并发症。
Neuro Oncol. 2014 Apr;16(4):589-93. doi: 10.1093/neuonc/nou001. Epub 2014 Jan 30.
3
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.拉罗替尼（anti-PD-1）治疗黑色素瘤的安全性和肿瘤应答。
N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.
4
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
Zotero 插件